Stable, high-level biosynthesis of complex natural products requires precise control of heterologous pathway expression, yet transcriptional architectures optimized on plasmids often fail when transferred to the chromosome. Here, we present ePathIntegrate, a genome-centric pathway engineering strategy that leverages CRISPR-associated transposases (CASTs) to ...
INTRODUCTION: After decades of regulatory marginalization, psychedelic compounds have reemerged as promising therapeutic tools in psychiatry, driven by unmet clinical needs in treatment-resistant mental disorders and by growing evidence of rapid and sustained effects on mood, cognition, and behavior. AREAS COVERED: This narrative review critically examined t...
Psychedelic-assisted psychotherapy (PAP) has re-emerged over the past decade as a promising therapeutic approach for a range of mental health conditions, including treatment-resistant depression, post-traumatic stress disorder, anxiety associated with life-threatening illness, and substance use disorders. Substances such as psilocybin, MDMA, ketamine, and LS...
ABSTRACT Psilocybin, an indole alkaloid of psychedelic mushrooms, has the potential to sustainably improve the treatment of several psychiatric diseases. So far, the psilocybin demand for clinical trials has been met by chemical synthesis. In this study, we pursued the biotechnological approach to develop a psilocybin production process utilizing an overprod...
Psychedelic research is progressing at breakneck speed and is creating new challenges for drug developers, regulatory authorities, and legislators. Most “classic” psychedelics undergoing clinical investigation are C-I controlled drugs with perceived high potential for abuse and no medical use. These and next-generation psychedelic drug-candidates require sci...
Psilocybin-assisted therapy (PAT) has been shown in early trials to reduce the symptoms of treatment-resistant depression (TRD). This study evaluated the cost-effectiveness of PAT as a third-line treatment for major depressive disorder compared to standard of care (SOC). We used an individual-level, probabilistic simulation model that portrays representative...
Abstract: Psilocybin mushrooms, also known as "magic mushrooms," have garnered significant attention for their psychoactive properties and potential therapeutic applications. This review explores the comprehensive morphology, pharmacognostic properties, and pharmacological activities of psilocybin-producing fungi. The unique morphological characteristics of ...
Recent experience with off-label use of ketamine and recent challenges experienced in research with MDMA and psilocybin provide additional perspectives on how best to continue development of experimental psychedelic medications. Andrews et al. [1] provide a valuable perspective by noting the parallels between the ongoing deregulation of cannabis and what is ...
Mental illness is a hot topic of concern worldwide. The psilocybin has great potential in the treatment of mental disorders, but there is still a research gap on whether it can truly be applied in the treatment of mental disorders. Therefore, this research explores the feasibility of psilocybin’s true application in the treatment of mental disorders by colle...
Psilocybin, a psychoactive alkaloid with hallucinogenic properties, exists in a variety of hallucinogenic mushrooms. As a study tool to imitate psychosis, psilocybin has aroused a lot of interest in the biological community due to its various possible therapeutic benefits. It is also a very popular and widely misused natural hallucinogens with distinct metab...
Traditional psychedelics are undergoing a transformation from recreational drugs, to promising pharmaceutical drug candidates with the potential to provide an alternative treatment option for individuals struggling with mental illness. Sustainable and economic production methods are thus needed to facilitate enhanced study of these drug candidates to support...
Abstract Psychoactive substances such as psilocybin and 3,4-methylenedioxy-methamphetamine (MDMA) are currently being investigated for a variety of psychiatric indications including major depressive disorder and post-traumatic stress disorder. It is critical that clinicians working in the mental health field understand the regulatory framework that balances ...
Psychiatric illnesses - such as major depressive disorder, anxiety disorder, substance use disorder, and posttraumatic stress disorder (PTSD) - are widely prevalent and represent a substantial health burden worldwide. Yet, conventional medications for mental illnesses often fail to provide relief to patients' disruptive and disabling symptoms. Existing and e...
Interest in the potential therapeutic efficacy of psilocybin and other psychedelic compounds has escalated significantly in recent years. To date, little is known regarding the biological activity of the psilocybin pathway intermediate, norbaeocystin, due to limitations around sourcing the phosphorylated tryptamine metabolite for in vivo testing. To address ...
Psilocybin is a tryptamine-derived psychoactive alkaloid found mainly in the fungal genus Psilocybe, among others, and is the active ingredient in so-called "magic mushrooms". Although its notoriety originates from its psychotropic properties and popular use as a recreational drug, clinical trials have recently recognized psilocybin as a promising candidate ...
